These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 38711004)

  • 1. Methyl CpG binding protein MBD2 has a regulatory role on the BRCA1 gene expression and its modulation by resveratrol in ER+, PR+ & triple-negative breast cancer cells.
    Sahu RK; Tandon S; Singh S; Das BC; Hedau ST
    BMC Cancer; 2024 May; 24(1):566. PubMed ID: 38711004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of resveratrol on the expression of a panel of genes interacting with the BRCA1 oncosuppressor in human breast cell lines.
    Le Corre L; Fustier P; Chalabi N; Bignon YJ; Bernard-Gallon D
    Clin Chim Acta; 2004 Jun; 344(1-2):115-21. PubMed ID: 15149879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. miR-638 mediated regulation of BRCA1 affects DNA repair and sensitivity to UV and cisplatin in triple-negative breast cancer.
    Tan X; Peng J; Fu Y; An S; Rezaei K; Tabbara S; Teal CB; Man YG; Brem RF; Fu SW
    Breast Cancer Res; 2014 Sep; 16(5):435. PubMed ID: 25228385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resveratrol exhibits diverse anti-cancer activities through epigenetic regulation of E-cadherin and p21 in triple-negative breast cancer cells.
    Sakamoto T; Tanimoto K; Eguchi H; Sasaki S; Tsuboi K; Hayashi SI; Ichihara S
    Breast Cancer; 2023 Sep; 30(5):727-738. PubMed ID: 37166625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liquiritigenin decreases tumorigenesis by inhibiting DNMT activity and increasing BRCA1 transcriptional activity in triple-negative breast cancer.
    Liang F; Zhang H; Gao H; Cheng D; Zhang N; Du J; Yue J; Du P; Zhao B; Yin L
    Exp Biol Med (Maywood); 2021 Feb; 246(4):459-466. PubMed ID: 32938226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Curcumin induces re‑expression of BRCA1 and suppression of γ synuclein by modulating DNA promoter methylation in breast cancer cell lines.
    Al-Yousef N; Shinwari Z; Al-Shahrani B; Al-Showimi M; Al-Moghrabi N
    Oncol Rep; 2020 Mar; 43(3):827-838. PubMed ID: 32020216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor effects of co-treatment of resveratrol with antitumor drugs in ER- and HER2-positive breast cancer cells are due to induction of apoptosis and modulation of estrogen receptor expression.
    Franceschi BT; Bezerra PHA; Torqueti MR
    Breast Cancer; 2024 Sep; 31(5):754-768. PubMed ID: 38780752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
    Blanchard Z; Paul BT; Craft B; ElShamy WM
    Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Flavonoid calycopterin triggers apoptosis in triple-negative and ER-positive human breast cancer cells through activating different patterns of gene expression.
    Moradi M; Gholipour H; Sepehri H; Attari F; Delphi L; Arefian E; Moridi Farimani M
    Naunyn Schmiedebergs Arch Pharmacol; 2020 Nov; 393(11):2145-2156. PubMed ID: 32617603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resveratrol enhances the sensitivity of FL118 in triple-negative breast cancer cell lines via suppressing epithelial to mesenchymal transition.
    Yar Saglam AS; Kayhan H; Alp E; Onen HI
    Mol Biol Rep; 2021 Jan; 48(1):475-489. PubMed ID: 33389483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Obesity-induced MBD2_v2 expression promotes tumor-initiating triple-negative breast cancer stem cells.
    Teslow EA; Mitrea C; Bao B; Mohammad RM; Polin LA; Dyson G; Purrington KS; Bollig-Fischer A
    Mol Oncol; 2019 Apr; 13(4):894-908. PubMed ID: 30636104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Promoter hypermethylation of p16, BRCA1 and RASSF1A genes in triple-negative breast cancer patients from Serbia.
    Kozomara Z; Supic G; Krivokuca A; Magic Z; Dzodic R; Milovanovic Z; Brankovic-Magic M
    J BUON; 2018; 23(3):684-691. PubMed ID: 30003738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A high expression ratio of RhoA/RhoB is associated with the migratory and invasive properties of basal-like Breast Tumors.
    Privat M; Cavard A; Zekri Y; Ponelle-Chachuat F; Molnar I; Sonnier N; Bignon YJ
    Int J Med Sci; 2020; 17(17):2799-2808. PubMed ID: 33162807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resveratrol modulates epigenetic regulators of promoter histone methylation and acetylation that restores BRCA1, p53, p21
    Chatterjee B; Ghosh K; Kanade SR
    Biofactors; 2019 Sep; 45(5):818-829. PubMed ID: 31317586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estrogen receptor-α36 is involved in icaritin induced growth inhibition of triple-negative breast cancer cells.
    Wang X; Zheng N; Dong J; Wang X; Liu L; Huang J
    J Steroid Biochem Mol Biol; 2017 Jul; 171():318-327. PubMed ID: 28529129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA deregulation in triple negative breast cancer reveals a role of miR-498 in regulating BRCA1 expression.
    Matamala N; Vargas MT; González-Cámpora R; Arias JI; Menéndez P; Andrés-León E; Yanowsky K; Llaneza-Folgueras A; Miñambres R; Martínez-Delgado B; Benítez J
    Oncotarget; 2016 Apr; 7(15):20068-79. PubMed ID: 26933805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Calycosin inhibits triple-negative breast cancer progression through down-regulation of the novel estrogen receptor-α splice variant ER-α30-mediated PI3K/AKT signaling pathway.
    Li Y; Hu S; Chen Y; Zhang X; Gao H; Tian J; Chen J
    Phytomedicine; 2023 Sep; 118():154924. PubMed ID: 37393829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic Activation of
    Donovan MG; Selmin OI; Doetschman TC; Romagnolo DF
    Nutrients; 2019 Oct; 11(11):. PubMed ID: 31652854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Schleichera oleosa Seed Extract Reduced the Proliferation of Breast Cancer by Regulating the BRCA1 and p16 Genes.
    Sahu RK; Kumar B; Singh R; Kumari S; Tandon S; Das BC; Hedau ST
    Asian Pac J Cancer Prev; 2022 Jan; 23(1):151-160. PubMed ID: 35092383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
    Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
    Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.